[1] [1] ALLEN E S, STRONCEK D F, REN J Q, et al. Autologous lymphapheresis for the production of chimeric antigen receptor T cells[J]. Transfusion, 2017, 57(5): 1133-1141.

[2] [2] BASAR R, DAHER M, REZVANI K. Next-generation cell therapies: the emerging role of CAR-NK cells[J]. Blood Adv, 2020, 4(22): 5868-5876.

[3] [3] MAJZNER R G, MACKALL C L. Tumor antigen escape from CAR T-cell therapy[J]. Cancer Discov, 2018, 8(10): 1219-1226.

[4] [4] LEKO V, ROSENBERG S A. Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors[J]. Cancer Cell, 2020, 38(4): 454-472.

[5] [5] LI Y R, ZHOU Y, KIM Y J, et al. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy[J]. Cell Rep Med, 2021, 2(11): 100449.

[6] [6] ROSENBERG S A, RESTIFO N P. Adoptive cell transfer as personalized immunotherapy for human cancer[J]. Science, 2015, 348(6230): 62-68.

[7] [7] ROWAN A G, PONNUSAMY K, REN H W, et al. Anti-T cell receptor V chain-specific CAR-iNKT cells as a precise strategy to treat mature T cell lymphomas[J]. Blood, 2022, 140(Supplement 1): 10257-10258.

[8] [8] WOLF B J, CHOI J E, EXLEY M A. Novel approaches to exploiting invariant NKT cells in cancer immunotherapy[J]. Front Immunol, 2018, 9: 384.

[9] [9] EXLEY M A, FRIEDLANDER P, ALATRAKCHI N, et al. Adoptive transfer of invariant NKT cells as immunotherapy for advanced melanoma: a phase I clinical trial[J]. Clin Cancer Res, 2017, 23(14): 3510-3519.

[10] [10] AOKI T, TAKAMI M, TAKATANI T, et al. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner[J]. Cancer Sci, 2020, 111(7): 2223-2233.

[11] [11] HARAGUCHI K, TAKAHASHI T, NAKAHARA F, et al. CD1d expression level in tumor cells is an important determinant for anti-tumor immunity by natural killer T cells[J]. Leuk Lymphoma, 2006, 47(10): 2218-2223.

[12] [12] BASSIRI H, DAS R, GUAN P, et al. iNKT cell cytotoxic responses control T-lymphoma growthin vitroandin vivo[J]. Cancer Immunol Res, 2014, 2(1): 59-69.

[13] [13] SULLIVAN B A, KRONENBERG M. Activation or anergy: NKT cells are stunned by alpha-galactosylceramide[J]. J Clin Invest, 2005, 115(9): 2328-2329.

[14] [14] BASSIRI H, DAS R, GUAN P, et al. iNKT cell cytotoxic responses control T-lymphoma growthin vitroandin vivo[J]. Cancer Immunol Res, 2014, 2(1): 59-69.

[15] [15] VAN KAER L, PAREKH V V, WU L. Invariant natural killer T cells: bridging innate and adaptive immunity[J]. Cell Tissue Res, 2011, 343(1): 43-55.

[16] [16] YAMASHITA K, ARIMOTO A, NISHI M, et al. Application of iNKT cell-targeted active immunotherapy in cancer treatment[J]. Anticancer Res, 2018, 38(7): 4233-4239.

[17] [17] BENDELAC A, SAVAGE P B, TEYTON L. The biology of NKT cells[J]. Annu Rev Immunol, 2007, 25: 297-336.

[18] [18] KRONENBERG M, GAPIN L. The unconventional lifestyle of NKT cells[J]. Nat Rev Immunol, 2002, 2(8): 557-568.

[19] [19] LI Y R, ZHOU Y, WILSON M, et al. Tumor-localized administration of -Galcer to recruit invariant natural killer T cells and enhance their antitumor activity against solid tumors[J]. Int J Mol Sci, 2022, 23(14): 7547.

[20] [20] BAE E A, SEO H, KIM I K, et al. Roles of NKT cells in cancer immunotherapy[J]. Arch Pharm Res, 2019, 42(7): 543-548.

[21] [21] BRENNAN P J, BRIGL M, BRENNER M B. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions[J]. Nat Rev Immunol, 2013, 13(2): 101-117.

[22] [22] JHUNJHUNWALA S, HAMMER C, DELAMARRE L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion[J]. Nat Rev Cancer, 2021, 21(5): 298-312.

[23] [23] KAWANO T, CUI J, KOEZUKA Y, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides[J]. Science, 1997, 278(5343): 1626-1629.

[24] [24] SMYTH M J, HAYAKAWA Y, TAKEDA K, et al. New aspects of natural-killer-cell surveillance and therapy of cancer[J]. Nat Rev Cancer, 2002, 2(11): 850-861.

[25] [25] BIRON C A, NGUYEN K B, PIEN G C, et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines[J]. Annu Rev Immunol, 1999, 17: 189-220.

[26] [26] CARNAUD C, LEE D, DONNARS O, et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells[J]. J Immunol, 1999, 163(9): 4647-4650.

[27] [27] MCCARTHY C, SHEPHERD D, FLEIRE S, et al. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation[J]. J Exp Med, 2007, 204(5): 1131-1144.

[28] [28] NAIR S, DHODAPKAR M V. Natural killer T cells in cancer immunotherapy[J]. Front Immunol, 2017, 8: 1178.

[29] [29] SRIRAM V, CHO S, LI P, et al. Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cells[J]. Proc Natl Acad Sci USA, 2002, 99(12): 8197-8202.

[30] [30] BRUTKIEWICZ R R, YUNES-MEDINA L, LIU J Y. Immune evasion of the CD1d/NKT cell axis[J]. Curr Opin Immunol, 2018, 52: 87-92.